SynthesisIntensive care medicine2016
Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis.
Synthesis in Intensive care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- The impact of antithrombin III supplementation on prognosis during extracorporeal membrane oxygenation: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Association between antithrombin levels and prognosis in patients with sepsis: a retrospective cohort study based on the MIMIC-IV and MIMIC-III databases.Journal of intensive care · 2026Article
- Clinical subphenotypes of sepsis based on mixed continuous and categorical data and differences in treatment effects: a cluster analysis of multicenter observational studies.Critical care (London, England) · 2026Observational
- CD163 and the FVIII/FXII ratio identified as novel biomarkers for early sepsis recognition.Frontiers in medicine · 2026Article
- Admission antithrombin III activity as a risk-enrichment marker for septic shock below the ISTH overt-DIC threshold.Frontiers in medicine · 2026Article
- Disseminated intravascular coagulation: cause, molecular mechanism, diagnosis, and therapy.MedComm · 2025Review
- Biomarkers of sepsis-induced coagulopathy: diagnostic insights and potential therapeutic implications.Annals of intensive care · 2025Review
- Proteomic characterization of molecular mechanisms of paraquat-induced lung injury in a mouse model.Respiratory research · 2025Article
- Prophylactic anticoagulant therapy is associated with improved survival in ICU patients with non-COVID-19 pneumonia: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- A comparison of anti-coagulation monitoring tests in ICU patients receiving a continuous infusion of unfractionated heparin.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2024Article
- Neutrophil extracellular traps contribute to immunothrombosis formation via the STING pathway in sepsis-associated lung injury.Cell death discovery · 2023Article
- Effects of Antithrombin on Persistent Inflammation, Immunosuppression, and Catabolism Syndrome among Patients with Sepsis-Induced Disseminated Intravascular Coagulation.Journal of clinical medicine · 2023Article
- How to manage coagulopathies in critically ill patients.Intensive care medicine · 2023Review
- Endothelial Damage and the Microcirculation in Critical Illness.Biomedicines · 2022Review
- Anticoagulation Management during Extracorporeal Membrane Oxygenation-A Mini-Review.Medicina (Kaunas, Lithuania) · 2022Review
- The antithrombosis effect of dehydroandrographolide succinate:Pharmaceutical biology · 2022Article
- Black Garlic and Thiosulfinate-Enriched Extracts as Adjuvants to Ceftriaxone Treatment in a Rat Peritonitis Model of Sepsis.Biomedicines · 2022Article
- Thrombin generation capacity is enhanced by low antithrombin activity and depends on the activity of the related coagulation factors.Thrombosis journal · 2022Article
- Gender-specific differences in haemostatic parameters and their influence on blood loss in bimaxillary surgery.Clinical oral investigations · 2022Article
- Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAntithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients.
methodsWe searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language.
resultsWe included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95% CI 0.88-1.03, I (2) = 0%, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95% Cl 0.88-1.03, I (2) = 0%, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95% CI 1.35-1.84, I (2) = 0%, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance.
conclusionsThere is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.